TBPH
Theravance Biopharma, Inc.
Biotechnology · Healthcare · United States
17.03
close · 2026-09-23
value
47
cheaper than peers47
quality
79
stronger fundamentals79
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 13.36× | 68 |
| price to sales | 7.98× | 62 |
| price to book | 3.05× | 57 |
| EV to EBITDA | 78.87× | 11 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 50.2% | 94 |
| operating margin | -33.1% | 66 |
| debt to equity | 13.9% | 55 |
| revenue growth | 15.0% | 46 |
4 of 4 measures available
Facts
| market cap | $884M |
| free cash flow | $22.5M |
| employees | 90 |
| first trade | 2014-05-16 |
| next earnings | 2026-08-10 |
| fundamentals updated | 2026-08-10 |